Literature DB >> 22517408

Life years lost--comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale.

N Patrik Brodin1, Ivan R Vogelius, Maja V Maraldo, Per Munck af Rosenschöld, Marianne C Aznar, Anne Kiil-Berthelsen, Per Nilsson, Thomas Björk-Eriksson, Lena Specht, Søren M Bentzen.   

Abstract

BACKGROUND: The authors developed a framework for estimating and comparing the risks of various long-term complications on a common scale and applied it to 3 different techniques for craniospinal irradiation in patients with pediatric medulloblastoma.
METHODS: Radiation dose-response parameters related to excess hazard ratios for secondary breast, lung, stomach, and thyroid cancer; heart failure, and myocardial infarction were derived from large published clinical series. Combined with age-specific and sex-specific hazards in the US general population, the dose-response analysis yielded excess hazards of complications for a cancer survivor as a function of attained age. After adjusting for competing risks of death, life years lost (LYL) were estimated based on excess hazard and prognosis of a complication for 3-dimensional conformal radiotherapy (3D CRT), volumetric modulated arc therapy (VMAT), and intensity-modulated proton therapy (IMPT).
RESULTS: Lung cancer contributed most to the estimated LYL, followed by myocardial infarction, and stomach cancer. The estimates of breast or thyroid cancer incidence were higher than those for lung and stomach cancer incidence, but LYL were lower because of the relatively good prognosis. Estimated LYL ranged between 1.90 years for 3D CRT to 0.28 years for IMPT. In a paired comparison, IMPT was associated with significantly fewer LYL than both photon techniques.
CONCLUSIONS: Estimating the risk of late complications is associated with considerable uncertainty, but including prognosis and attained age at an event to obtain the more informative LYL estimate added relatively little to this uncertainty.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22517408      PMCID: PMC3402656          DOI: 10.1002/cncr.27536

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (w(R)). A report of the International Commission on Radiological Protection.

Authors: 
Journal:  Ann ICRP       Date:  2003

2.  Estimation of radiation-induced cancer from three-dimensional dose distributions: Concept of organ equivalent dose.

Authors:  Uwe Schneider; Daniel Zwahlen; Dieter Ross; Barbara Kaser-Hotz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

3.  Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.

Authors:  Lois B Travis; Deirdre Hill; Graça M Dores; Mary Gospodarowicz; Flora E van Leeuwen; Eric Holowaty; Bengt Glimelius; Michael Andersson; Eero Pukkala; Charles F Lynch; David Pee; Susan A Smith; Mars B Van't Veer; Timo Joensuu; Hans Storm; Marilyn Stovall; John D Boice; Ethel Gilbert; Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2005-10-05       Impact factor: 13.506

4.  Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma.

Authors:  N Patrik Brodin; Per Munck Af Rosenschöld; Marianne C Aznar; Anne Kiil-Berthelsen; Ivan R Vogelius; Per Nilsson; Birgitta Lannering; Thomas Björk-Eriksson
Journal:  Acta Oncol       Date:  2011-08       Impact factor: 4.089

5.  Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors.

Authors:  Raymond Miralbell; Antony Lomax; Laura Cella; Uwe Schneider
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

6.  Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries.

Authors:  Sarah C Darby; Paul McGale; Carolyn W Taylor; Richard Peto
Journal:  Lancet Oncol       Date:  2005-08       Impact factor: 41.316

7.  Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study.

Authors:  Xiangkui Mu; Thomas Björk-Eriksson; Simeon Nill; Uwe Oelfke; Karl-Axel Johansson; Giovanna Gagliardi; Lennart Johansson; Mikael Karlsson; Dr Björn Zackrisson
Journal:  Acta Oncol       Date:  2005       Impact factor: 4.089

8.  Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma.

Authors:  Jonas Lundkvist; Mattias Ekman; Suzanne Rehn Ericsson; Bengt Jönsson; Bengt Glimelius
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

9.  The risk of developing a second cancer after receiving craniospinal proton irradiation.

Authors:  Wayne D Newhauser; Jonas D Fontenot; Anita Mahajan; David Kornguth; Marilyn Stovall; Yuanshui Zheng; Phillip J Taddei; Dragan Mirkovic; Radhe Mohan; James D Cox; Shiao Woo
Journal:  Phys Med Biol       Date:  2009-03-20       Impact factor: 3.609

10.  Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study.

Authors:  Ann C Mertens; Qi Liu; Joseph P Neglia; Karen Wasilewski; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Yutaka Yasui
Journal:  J Natl Cancer Inst       Date:  2008-09-23       Impact factor: 11.816

View more
  20 in total

1.  Retrospective estimation of heart and lung doses in pediatric patients treated with spinal irradiation.

Authors:  Daniel Gasic; Per Munck Af Rosenschöld; Ivan R Vogelius; Maja V Maraldo; Marianne C Aznar; Karsten Nysom; Thomas Björk-Eriksson; Søren M Bentzen; Nils Patrik Brodin
Journal:  Radiother Oncol       Date:  2018-05-30       Impact factor: 6.280

2.  Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma.

Authors:  Aaron P Brown; Christian L Barney; David R Grosshans; Mary Frances McAleer; John F de Groot; Vinay K Puduvalli; Susan L Tucker; Cody N Crawford; Meena Khan; Soumen Khatua; Mark R Gilbert; Paul D Brown; Anita Mahajan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-20       Impact factor: 7.038

3.  Use of PET/CT instead of CT-only when planning for radiation therapy does not notably increase life years lost in children being treated for cancer.

Authors:  Josefine S Kornerup; Patrik Brodin; Charlotte Birk Christensen; Thomas Björk-Eriksson; Anne Kiil-Berthelsen; Lise Borgwardt; Per Munck Af Rosenschöld
Journal:  Pediatr Radiol       Date:  2014-11-07

4.  PET/CT-guided treatment planning for paediatric cancer patients: a simulation study of proton and conventional photon therapy.

Authors:  J S Kornerup; N P Brodin; T Björk-Eriksson; C Birk Christensen; A Kiil-Berthelsen; M C Aznar; C Hollensen; E Markova; P Munck Af Rosenschöld
Journal:  Br J Radiol       Date:  2014-12-12       Impact factor: 3.039

Review 5.  Surveillance for Late Effects in Childhood Cancer Survivors.

Authors:  Wendy Landier; Roderick Skinner; W Hamish Wallace; Lars Hjorth; Renée L Mulder; F Lennie Wong; Yutaka Yasui; Nickhill Bhakta; Louis S Constine; Smita Bhatia; Leontien C Kremer; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2018-06-06       Impact factor: 44.544

Review 6.  Proton therapy for the treatment of children with CNS malignancies.

Authors:  Radhika Sreeraman; Daniel J Indelicato
Journal:  CNS Oncol       Date:  2014-03

7.  The risk of late effects following pediatric and adult radiotherapy regimens in Hodgkin lymphoma.

Authors:  Anni Young Lundgaard; Lisa Lyngsie Hjalgrim; Laura Ann Rechner; Michael Lundemann; N Patrik Brodin; Morten Joergensen; Lena Specht; Maja Vestmoe Maraldo
Journal:  Strahlenther Onkol       Date:  2020-12-09       Impact factor: 3.621

Review 8.  Clinical controversies: proton therapy for pediatric tumors.

Authors:  Thomas E Merchant
Journal:  Semin Radiat Oncol       Date:  2013-04       Impact factor: 5.934

9.  Cost of survivorship care and adherence to screening-aligning the priorities of health care systems and survivors.

Authors:  Catherine Benedict; Jason Wang; Marina Reppucci; Charles L Schleien; Jonathan D Fish
Journal:  Transl Behav Med       Date:  2021-02-11       Impact factor: 3.046

10.  Preclinical Modeling of Image-Guided Craniospinal Irradiation for Very-High-Risk Medulloblastoma.

Authors:  Stephanie M C Smith; Brandon M Bianski; Brent A Orr; Gretchen Harknett; Arzu Onar-Thomas; Richard J Gilbertson; Thomas E Merchant; Martine F Roussel; Christopher L Tinkle
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-10-23       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.